Hjem › Akut myelogen leukemi › Utah
Kliniske studier for Akut myelogen leukemi i Utah
17 studier for Akut myelogen leukemi søker deltakere på steder i Utah.
Byer i Utah
Offisiell studietekst (engelsk)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Intermountain Healthcare LDS Hospital, Salt Lake City
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Primary Children's Hospital, Salt Lake City
RekruttererFase 3
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Huntsman Cancer Institute, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04996875A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Primary Children's Hospital, Salt Lake City
RekruttererFase 1/2
Opp til 22 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Primary Children's Hospital, Salt Lake City
RekruttererFase 3
29 Days – 21 Years · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Utah, Salt Lake City
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545Ivosidenib as Post-HSCT Maintenance for AML
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 18. jun. 2026 · NCT06707493Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
RekruttererFase 1
Alder 13 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT04771572Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- University of Utah, Salt Lake City
RekruttererFase 1
Opp til 21 år · Alle kjønn · Oppdatert 22. apr. 2026 · NCT05101551A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.